MD Anderson Cancer Center
Recent study on drug for newly diagnosed glioblastoma patients – CNL
Bevacizumab offers no benefit for newly diagnosed glioblastoma (brain) cancer patients, MD Anderson-led study finds. Mark Gilbert, M.D., professor in Neuro-Oncology at MD Anderson Cancer Center, and Minesh Mehta, M.D., Ph.D., chairman of Radiation Oncology at the University of Maryland School of Medicine, discuss their study in the front line setting for the treatment of glioblastoma.
Loading the Audio Player...

Title: Recent study on drug for newly diagnosed glioblastoma patients – CNL
Summary: Bevacizumab offers no benefit for newly diagnosed glioblastoma (brain) cancer patients, MD Anderson-led study finds. Mark Gilbert, M.D., professor in Neuro-Oncology at MD Anderson Cancer Center, and Minesh Mehta, M.D., Ph.D., chairman of Radiation Oncology at the University of Maryland School of Medicine, discuss their study in the front line setting for the treatment of glioblastoma.
Keywords: cnl, cancer newsline, Bevacizumab, glioblastoma, brain cancer, study, research, newly diagnosed, mark gilbert, minesh Mehta, cancer treatment, radiation, chemotherapy integratedComm, Communications - Integrated Media
Transcript: